Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Journal of Hematology & Oncology2013cited by 94position: middledoi
Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts